Previous Episode: Quality in Healthcare
Next Episode: Compounded GLP1s

This episode discusses the 2023 Inflation Reduction Act and HHS's authority to negotiate prices for high-cost drugs in Medicare Part D. In addition to the initial list of 10 drugs, HHS is now focused on medications used in the hospital and covered under Medicare Part B.
 
The GameChanger
HHS updates the Inflation Reduction Act that will impact over 750, 000 people.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Jake Galdo, PharmD, MBA, BCPS, BCGP
CEO
Seguridad

Reference
Reduced Coinsurance for Certain Part B Rebatable Drugs Under the Medicare Prescription Drug  Inflation Rebate Program
 

HHS Announces Savings for 41 Prescription Drugs Thanks to Inflation Rebates from the Biden-Harris Administration’s Lower Cost Prescription Drug Law


Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the monetary impact of the Inflation Reduction Act.
2. Discuss how the Medicare Part B drug addition will benefit patients.

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-136-H04-P
Initial release date: 4/08/2024
Expiration date: 04/08/2025
Additional CPE details can be found here.


Follow CEimpact on Social Media:
LinkedIn
Instagram